References
- Cascinu S, Georgoulias V, Kerr D, Maughan T, Labianca R, Ychou M. Colorectal cancer in the adjuvant set-ting: perspectives on treatment and the role of prognostic fac-tors. Ann Oncol 1904; 14 Suppl 2: ii25-ii29.
- Wilke HJ, Van Cutsem E. Current treatments and future perspectives in colorectal and gastric cancer. Ann Oncol 1904; 14 Suppl 2: ii49-ii55.
- Saltz LB, Meropol NJ, Loehrer PJS, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22 (7): 1201–8.
- Mathijssen RH, Marsh S, Karlsson MO et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9 (9): 3246–53.
- Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60 (24): 6921–6.
- Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22 (8): 1382-8.
- Iyer L, Das S, Janisch L et al. UGT1A1*28 polymor-phism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2 (1): 43-7.
- Ando Y, Saka H, Ando M et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60 (24): 6921–6.
- Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347 (9001): 578–81.
- Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 2002; 24 (1): 111–6.
- Sai K, Saeki M, Saito Y et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with can-cer. Clin Pharmacol Ther 2004; 75 (6): 501-15.
- Metzger R, Leichman CG, Danenberg KD et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16 (1): 309-16.
- Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1 (1): 65-70.
- Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IV514 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12 (7): 555–8.
- Kishi S, Griener J, Cheng C et al. Homocysteine, phar-macogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21 (16): 3084–91.
- Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001; 22 (4): 195–201.
- Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI. Effect of the methylenetetrahydrofolate reductase C677T poly-morphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004; 96 (2): 134–44.
- Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R. Methylenetetrahydrofolate reductase poly-morphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9 (5): 1611–5.
- Chiusolo P, Reddiconto G, Casorelli I et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002; 13 (12): 1915-8.
- Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myeloge-nous leukemia. J Clin Oncol 2004; 22 (7): 1268–75.
- Toffoli G, Russo A, Innocenti F et al. Effect of methyl-enetetrahydrofolate reductase 677C—>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003; 103 (3): 294-9.
- Quinn CT, Griener JC, Bottiglieri T, Hyland K, Farrow A, Kamen BA. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 1997; 15 (8): 2800–6.
- Etienne MC, Ilc K, Formento JL et al. Thymidylate syn-thase and methylenetetrahydrofolate reductase gene polymor-phisms: relationships with 5-fluorouracil sensitivity. Br J Cancer 2004; 90 (2): 526–34.